DCVAC/PCa (SOTIO) is a cell-based cancer vaccine composed of autologous dendritic cells which are activated to recognize a prostate cancer cell line. When infused into patients, the primed dendritic cells cause activation of T cells, which can then recognize and destroy prostate cancer tumor cells.
TABLE OF CONTENTS
4 Product Profiles
4 DCVAC/PCa : Prostate cancer
LIST OF FIGURES
9 Figure 1: DCVAC/PCa for prostate cancer – SWOT analysis
10 Figure 2: Datamonitor Healthcare’s drug assessment summary of DCVAC/PCa for prostate cancer
11 Figure 3: Datamonitor Healthcare’s drug assessment summary of DCVAC/PCa for prostate cancer
13 Figure 4: DCVAC/PCa sales for prostate cancer across the US, Japan, and five major EU markets, by country, 2017–26
LIST OF TABLES
4 Table 1: DCVAC/PCa drug profile
6 Table 2: DCVAC/PCa Phase III trial in prostate cancer
8 Table 3: DCVAC/PCa Phase I/II data in prostate cancer
14 Table 4: DCVAC/PCa sales for prostate cancer across the US, Japan, and five major EU markets, by country ($m), 2017–26
This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.